Table 1 Clinicopathological characteristics of samples in the whole cohort and in subgroup defined according to the GEF/GAP metagene-based classifier
From: ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer
Characteristics | N (%) | GEF/GAP metagene | p Value | |
|---|---|---|---|---|
Down | Up | |||
Age at diagnosis (years) | 3.46E-14 | |||
≤50 | 2540 (36%) | 1112 (32%) | 1428 (40%) | |
>50 | 4488 (64%) | 2388 (68%) | 2100 (60%) | |
Pathological type | 1.21E-02 | |||
Ductal | 3979 (79%) | 1998 (77%) | 1981 (80%) | |
Lobular | 498 (10%) | 263 (10%) | 235 (10%) | |
Other | 574 (11%) | 325 (13%) | 249 (10%) | |
Pathological tumour size (pT) | 0.133 | |||
pT1 | 2113 (38%) | 1100 (39%) | 1013 (36%) | |
pT2 | 2923 (52%) | 1439 (51%) | 1484 (53%) | |
pT3 | 595 (11%) | 304 (11%) | 291 (10%) | |
Pathological axillary node status (pN) | 0.239 | |||
0 | 3446 (56%) | 1741 (56%) | 1705 (55%) | |
1 | 2743 (44%) | 1344 (44%) | 1399 (45%) | |
Pathological grade | 1.00E-06 | |||
1 | 721 (11%) | 442 (14%) | 279 (9%) | |
2 | 2573 (41%) | 1478 (48%) | 1095 (34%) | |
3 | 2986 (48%) | 1181 (38%) | 1805 (57%) | |
ER mRNA status | 2.29E-153 | |||
Negative | 2764 (31%) | 811 (18%) | 1953 (43%) | |
Positive | 6218 (69%) | 3680 (82%) | 2538 (57%) | |
PR mRNA status | 8.62E-53 | |||
Negative | 4670 (52%) | 1976 (44%) | 2694 (60%) | |
Positive | 4255 (48%) | 2489 (56%) | 1766 (40%) | |
ERBB2 mRNA status | 0.00021 | |||
Negative | 7884 (88%) | 4000 (89%) | 3884 (86%) | |
Positive | 1098 (12%) | 491 (11%) | 607 (14%) | |
Molecular subtype | 1.00E-06 | |||
HR+/HER2− | 5929 (66%) | 3532 (79%) | 2397 (54%) | |
HER2+ | 1098 (12%) | 491 (11%) | 607 (14%) | |
TN | 1936 (22%) | 463 (10%) | 1473 (33%) | |
Metastatic relapse | 6.81E-06 | |||
No | 3127 (77%) | 1606 (80%) | 1521 (74%) | |
Yes | 923 (23%) | 396 (20%) | 527 (26%) | |
Follow-up, median (range) | 42 (1–232 | 38 (1–221) | 37 (1–232) | 0.48 |
5-year MFS, % [95% CI] | 71% [69–74] | 75% [72–79] | 67% [64–71] | 5.09E-04 |
